Results 231 to 240 of about 193,970 (395)

Clinical Utility and Prognostic Implications of Circulating Cell-Free DNA in Biliary Tract Cancer. [PDF]

JCO Precis Oncol
Cowzer D, Darmofal M, Seier K, Thummalapalli R, Walch H, El Dika I, Khalil DN, Park W, Dhyani A, Yaqubie A, Shin P, Gholami S, Erinjeri J, Wei AC, Yeh R, Do RK, Basturk O, Shia J, Cercek A, Schram A, Chatila WK, Schultz N, O'Reilly EM, Gonen M, Berger MF, Solit DB, Abou-Alfa GK, Jarnagin W, Harding JJ.   +28 more
europepmc   +1 more source

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of sacituzumab govitecan for breast cancer, fruquintinib for colorectal cancer, amivantamab for lung cancer, repotrectinib for lung cancer, tasurgratinib for biliary tract cancer, enfortumab vedotin plus pembrolizumab for urothelial cancer, and dabrafenib plus trametinib for glioma in Japan [PDF]

Noriomi Matsumura, Masaki Mandai
openalex   +1 more source

Advances in the Diagnosis, Treatment, and Management of Liver Nodules: A Comprehensive Review

Portal Hypertension &Cirrhosis, EarlyView.
Liver nodules commonly occur due to various causes, some of which are malignant or may undergo malignant transformation, leading to disease progression or delayed detection in clinical practice. The widespread use of imaging methods has increased the detection rate of liver nodules. Furthermore, precision medicine techniques and artificial intelligence
Chang Gao, Dongyang Chen, Youpeng Chen
wiley   +1 more source

Immune-Checkpoint Inhibitors for Biliary Tract Cancer: Who Benefits and What Is Next? [PDF]

Cancers (Basel)
Ceniceros L, Torre M, Landa Magdalena A, Sangro P, Argemí J, D'Avola D, Sangro B, Ponz-Sarvisé M.   +7 more
europepmc   +1 more source

Prognostic factors in patients with advanced biliary tract cancer (BTC) who showed durable disease control with first-line gemcitabine plus cisplatin (GemCis)

, 2018
Jaewon Hyung, Changhoon Yoo, K.-P. Kim, Bum Joon Kim, Jae Ho Jeong, Heung-Moon Chang, Baek‐Yeol Ryoo   +6 more
openalex   +1 more source

Impact of Obesity and MASH on Zonal Hepatocellular Statin Exposure: Pharmacodynamic Insights From a Permeability‐Limited Multicompartment Liver Model

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
Obesity, MASH and Statins: Insights from a PBPK/PD Zonal Liver Model. ABSTRACT Statins are frequently prescribed for hyperlipidemia, a common comorbidity in patients with obesity and/or metabolic dysfunction‐associated steatohepatitis (MASH). However, limited knowledge exists on how MASH may alter statin disposition within hepatocytes where the statin ...
William A. Murphy, Noora Sjöstedt, Mailys De Sousa Mendes, Mattie Hartauer, Kim L. R. Brouwer, Sibylle Neuhoff   +5 more
wiley   +1 more source

Durvalumab plus cisplatin and gemcitabine in advanced biliary tract cancer: can we do it better? [PDF]

Hepatobiliary Surg Nutr
Rimini M, Casadei-Gardini A.
europepmc   +1 more source

Transplantation and other aspects of surgery of the liver [PDF]

, 1984
Iwatsuki, S, Shaw, BW, Starzl, TE, Van Thiel, DH   +3 more
core  

Physiologically‐Based Pharmacokinetic Modeling to Support Pediatric Clinical Development: An IQ Working Group Perspective on the Current Status and Challenges

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Pediatric extrapolation strategies issued by health authorities have streamlined pediatric drug development and reduced the unnecessary burden of conducting pediatric clinical studies. In line with these strategies, physiologically based pharmacokinetic (PBPK) models have been utilized extensively for initial dosing regimen and sampling ...
James W. T. Yates, Michael Zientek, Kunal S. Taskar, Wen Lin, Tycho Heimbach, Stefan Willmann, Jessica Rehmel, Neil Parrott, Michael Hanley, Justine Badee, Yuan Chen, Susan Cole, Loeckie De Zwart, Sebastian Haertter, Rongrong Jiang, Masakatsu Kotsuma, Guiqing Liang, Yu‐Wei Lin, Jing Liu, Ying Ou, Juliane Rascher, Naveed A. Shaik, Jan Wahlstrom, Xiaofeng Wang, Guangqing Xiao, Ka Lai Yee, S. Y. Amy Cheung   +26 more
wiley   +1 more source

Durvalumab in Advanced Biliary Tract Cancer: Real-World Data From a Large Cohort of Patients Across Multiple International Centers. [PDF]

Liver Int
Rimini M, Fornaro L, Ikeda M, Abidoye O, Lucchetti J, Antonuzzo L, Kim JW, Nichetti F, Saborowski A, Pressiani T, Vivaldi C, Rapposelli IG, Peeters F, Braconi C, Pinato DJ, Tamburini E, Pircher C, Tamberi S, Castet F, Verrico M, Parisi A, Couto N, Chon HJ, Martirena A, Lamarca A, Landriscina M, Fimkelmeier F, Oneda E, Avallone A, Dell'Aquila E, Perkhofer L, Kim IH, Pinto CMS, Garajova I, Kang B, Corallo S, Fenocchio E, Farinea G, Pastorino A, Diana A, Changhoon Y, Schirripa M, Rodriquenz MG, Scartozzi M, Zumstein L, Ghidini M, Prager GW, Aprile G, Spinelli GP, Yung-Yeh S, Chan S, Warmington E, Lancianese A, Bekaii-Saab T, Lavacchi D, Kang M, Lonardi S, Vogel A, Prete AA, Bozzarelli S, Salani F, Persano M, Masi G, Balsano R, Niger M, Camera S, Passeri L, Ferrara M, Satake T, Rimassa L, Casadei-Gardini A.   +70 more
europepmc   +1 more source